Lemor M, Yeo J H, Glaser B M
Arch Ophthalmol. 1986 Aug;104(8):1226-9. doi: 10.1001/archopht.1986.01050200132067.
In proliferative vitreoretinopathy and trauma, long-term reattachment of the retina is often prevented by the formation of contractile cellular membranes on the retinal surface and within the vitreous cavity. Colchicine, a well-documented inhibitor of microtubule assembly, is a potent inhibitor of retinal pigment epithelium cell, astrocyte, and fibroblast proliferation and migration. To study the therapeutic value of orally administered colchicine, we used an experimental animal model in which intravitreally injected platelet-derived growth factor and fibronectin produced traction retinal detachments in rabbits. With oral administration of colchicine, we were able to decrease the incidence and severity of traction retinal detachment from 74% in controls (20 of 27 eyes) to 29.6% in the treated animals (eight of 27 eyes) at five weeks (P less than .0009). These results, and the apparent lack of retinal and systemic toxicity, suggest that oral therapy with colchicine may prove to be of value in the treatment of human disease.
在增殖性玻璃体视网膜病变和外伤中，视网膜表面和玻璃体内形成的收缩性细胞膜常常会阻碍视网膜的长期复位。秋水仙碱是一种有充分文献记载的微管组装抑制剂，它能有效抑制视网膜色素上皮细胞、星形胶质细胞和成纤维细胞的增殖与迁移。为了研究口服秋水仙碱的治疗价值，我们使用了一种实验动物模型，即向兔眼玻璃体内注射血小板衍生生长因子和纤连蛋白，从而引发牵引性视网膜脱离。通过口服秋水仙碱，我们能够将牵引性视网膜脱离的发生率和严重程度在五周时从对照组的74%（27只眼中的20只）降至治疗组动物的29.6%（27只眼中的8只）（P小于0.0009）。这些结果以及明显缺乏视网膜和全身毒性表明，秋水仙碱口服疗法可能在人类疾病治疗中具有价值。
